摘要
核因子-κappa B (NF-κB) 是炎症通路的一个关键转录因子家族,在各种癌症(如乳腺癌、肺癌、肝癌、胰腺癌、前列腺癌和多种类型的淋巴瘤)的进展中发挥着重要作用。 NF-κB 在炎症和癌症之间发展出一种内在的关系。它是控制恶性细胞和肿瘤前细胞阻止基于程序性细胞死亡的肿瘤监测通道的能力的关键因素。由于其在各种癌症的发生和进展中具有重要意义,因此已成为癌症治疗的极好靶点。新兴的靶向疗法提供了很多希望,从而完全阻断单个蛋白质或通常的靶酶。几种天然化合物通过抑制各种癌症类型的 NF-κB 通路显示出抗癌和抗炎活性。已经报道了大约 750 种 NF-κB 的天然和合成抑制剂。这些抑制剂包括微生物和病毒蛋白、小 RNA/DNA、抗氧化剂、小分子、肽和工程化的组成型活性多肽,所有这些都可能抑制经典和替代 NF-κB 途径。因此,使用天然和合成化合物阻断或靶向 NF-κB 信号通路可能是治愈 NF-κB 诱导的肿瘤的潜在机制。
关键词: 癌症、NF-κB、NIK、抑制剂、NEMO、IKKβ。
Current Medicinal Chemistry
Title:A Critical Transcription Factor NF-κB as a Cancer Therapeutic Target and its Inhibitors as Cancer Treatment Options
Volume: 28 Issue: 21
关键词: 癌症、NF-κB、NIK、抑制剂、NEMO、IKKβ。
摘要: Nuclear Factor-κappa B (NF-κB) is a family of critical transcription factors of the inflammatory pathway and plays an imperative role in the progression of various cancers such as breast, lung, liver, pancreatic, prostate and multiple types of lymphoma. NF- κB develops an inherent relationship between inflammation and cancer. It is a crucial factor that controls the ability of malignant and pre-neoplastic cells to prevent programmed cell death-based tumor-surveillance channels. Due to its high significance in the onset and progression of various cancers, it has become an excellent target for cancer therapy. The emerging targeted therapies provide a lot of hope, whereby a single protein or generally the target enzyme is completely blocked. Several natural compounds have shown anticancer and anti-inflammatory activities by inhibiting the NF-κB pathway in various cancer types. About 750 natural and synthetic inhibitors of the NF-κB have been reported. These inhibitors include microbial and viral proteins, small RNA/DNA, antioxidants, small molecules, peptides, and engineered constitutively active polypeptides, all of which may inhibit canonical and alternative NF-κB pathways. Thus, blocking or targeting the NF-κB-signaling pathways using natural and synthetic compounds could be a potential mechanism to cure the NF-κB induced tumors.
Export Options
About this article
Cite this article as:
A Critical Transcription Factor NF-κB as a Cancer Therapeutic Target and its Inhibitors as Cancer Treatment Options, Current Medicinal Chemistry 2021; 28 (21) . https://dx.doi.org/10.2174/0929867327666201111142307
DOI https://dx.doi.org/10.2174/0929867327666201111142307 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Glioma and Neurokinin-1 Receptor Antagonists: A New Therapeutic Approach
Anti-Cancer Agents in Medicinal Chemistry Establishment of Cholinergic Neuron-like Cell Lines with Differential Vulnerability to Nitrosative Stress
Current Neurovascular Research Targeted Vascular Drug Delivery in Cerebral Cancer
Current Pharmaceutical Design Therapeutic Strategies to Target TGF-β in the Treatment of Bone Metastases
Current Pharmaceutical Biotechnology Editorial [Hot Topic: Gliomas: Current Issues in Diagnosis and Treatment (Guest Editor: Stephan Ulmer)]
Current Medical Imaging The Chemical Defensive System in the Pathobiology of Idiopathic Environment- Associated Diseases
Current Drug Metabolism Small and Long Non-Coding RNAs: Novel Targets in Perspective Cancer Therapy
Current Genomics Targeting ErbB3: the New RTK(id) on the Prostate Cancer Block
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) In Vitro Synergistic Interaction between DTA0100 and Radiation in Human Cancer Cell Lines
Anti-Cancer Agents in Medicinal Chemistry Can Breast Cancer Stem Cells Evade the Immune System?
Current Medicinal Chemistry Stability Testing During Development of Nanopharmaceuticals
Pharmaceutical Nanotechnology An Expanding Appreciation of the Role Chemokine Receptors Play in Cancer Progression
Current Pharmaceutical Design Role of ncRNAs in Development, Diagnosis and Treatment of Human Cancer
Recent Patents on Anti-Cancer Drug Discovery Apoptosis Induction by Ultrasound and Microbubble Mediated Drug Delivery and Gene Therapy
Current Molecular Medicine Inhibition of Autophagy Strengthens Celastrol-Induced Apoptosis in Human Pancreatic Cancer In Vitro and In Vivo Models
Current Molecular Medicine Recent Advances of Aminopyrimidines in Multicomponent Reactions
Current Organic Chemistry Radionuclide Antibody-Conjugates, a Targeted Therapy Towards Cancer
Current Radiopharmaceuticals NAD+ Metabolism and NAD+-Dependent Enzymes: Promising Therapeutic Targets for Neurological Diseases
Current Drug Targets C-glycosyl Flavone from Urginea indica Inhibits Growth and Dissemination of Ehrlich Ascites Carcinoma Cells in Mice
Anti-Cancer Agents in Medicinal Chemistry Phospholipase A2 Isoforms as Novel Targets for Prevention and Treatment of Inflammatory and Oncologic Diseases
Current Drug Targets